#Entering #global #multicenter #clinical #trial #stage #Jingfang #Medicine #completed #hundreds #millions #yuan #financing
It is reported that,Innovative drug developer“Jinfang Medicine” has recently completed hundreds of millions of yuan in B+ round of financing.This round of financing was led by Northern Light Venture Capital, with investors including Huimei Capital and Leading CapitalXingyuan Zhitong acted as the exclusive financial advisor for this transaction, as well as the original shareholders CDH Investment, Pan Lin Capital and other institutions.
“Jinfang Medicine” has entered the development stage of global multi-center clinical trials. This round of financing will be used to accelerate the company’s current product development and clinical trials, optimize the research and development system, and open the industrialization layout in parallel. Prior to this, the company also received nearly 400 million yuan in Series B investment in March 2020.
“Jingfang Medicine” was established in 2017 and is an innovative drug developer. With immunology as the core, the company focuses on multiple therapeutic areas such as tumors and autoimmune diseases, focusing on innovative targets and corresponding indications that have not yet been clinically verified. The new drug varieties independently developed at present are all original “global new” products.
“Jinfang Pharmaceutical” product pipeline
Specifically, “Jingfang Medicine” has established a tumor and immunological drug development platform based on immunological research. The first wave of the company’s pipeline of R&D projects is to mediate the tumor microenvironment as the entry point; the second type of project is the development of new drugs for new subtypes of tumor mature target families; the third type of project is the research and development of new drugs for mature immune targets. Including new small molecule drugs and biological macromolecular drugs.
Dr. Qiang Lu, Chairman of “Jinfang Medicine”, said: At present, the company has entered a new stage of global multi-center clinical trials. This year it is expected that a number of clinical studies will be carried out in China, the United States, and Australia, and the industrialization layout has begun to stabilize Advance.
In terms of the founding team, Dr. Qiang Lu, the chairman of “Jinfang Pharmaceutical”, served as senior R&D director at Wyeth and Novartis Pharmaceuticals in the United States. After returning to China, he served as Vice President of WuXi AppTec, Chief Scientific Officer of Yangtze River Pharmaceutical Group, and Yu Heng The chief scientific officer of the pharmaceutical industry and the senior vice president of operations of CStone Pharmaceuticals has more than 20 years of experience in scientific research and industry, and has led a number of drug research and development projects into the establishment and application of clinical and transnational platforms. CeoLan JiongPhDWorked at Traid Therapeutics Inc, Neurogen Corp, Novartis Pharmaceuticals, Shanghai Hengrui and Yangtze River Pharmaceuticals,With more than 20 years of experience in scientific research and industry, involving the development and research of anti-cancer, anti-inflammatory, antibacterial, metabolic and central nervous drugs, he has led the development of 13 clinical compounds and multiple preclinical compounds.
Editor: Cai Shuning
Extended reading: Aiming at “global new” innovative drugs, “Jingfang Medicine” received nearly 400 million yuan in round B investment